World Journal of Surgery · 2011 · 45 citations · 43 references
MedicineEndocrinologySurgeryDiabetologyGeneral SurgeryDiabetes ManagementDiabetes MellitusGastrointestinal InterventionsGastrointestinal SurgeryLaparoscopic SurgeryMinimally Invasive SurgeryColonic InterpositionGlycemic Control After SurgeryLaparoscopic Bariatric SurgeryLaparoscopic Colorectal SurgeryLaparoscopic GastrectomyLaparoscopic Gastrointestinal Surgery
BACKGROUND: Standard surgical procedures used for the treatment of morbid obesity constitute optional treatments for type 2 diabetes mellitus (T2DM). The aim of the present study was to evaluate the short- and mid-term effects of laparoscopic sleeve gastrectomy (SG) with ileal interposition (II) in T2DM patients (n = 30). METHODS: The variables investigated were the feasibility of the procedure, remission/alleviation of the disease, morbidity, mortality, and weight loss. Patients were followed during a period of 6-18 months after surgery. RESULTS: The average time required for the surgical procedure was 181.47 ± 53.23 min, and the mean duration of postoperative hospital stay was 3.17 ± 0.79 days. There were no intraoperative complications, and none of the patients required conversion to open surgery. Postoperatively, all patients experienced a significant weight loss: i.e., the mean body mass index (BMI) values prior to and following surgery were significantly different (P = 0.0001). Postoperative levels of glycosylated hemoglobin, fasting glucose, and fructosamine were significantly reduced (P = 0.0001, 0.0001, and 0.0004, respectively) from those detected prior to surgery. Remission of T2DM was observed in 80% of the patients over the follow-up period, and these subjects no longer required treatment with hypoglycemic drugs or diet. The remaining 20% of patients presented significant improvement in their condition but needed an oral hypoglycemic medication. CONCLUSIONS: Adequate glycemic control, adjustable weight loss, and absence of nutritional deficiencies were the main benefits offered by the surgical intervention. The results indicate that SG/II treatment could be a promising alternative for patients with T2DM.
43
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2010 · 14K citations · Full text
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Masayasu Kojima, Hiroshi Hosoda, Yukari Date et al. · Nature · 1999 · 8.5K citations
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2009 · 5.5K citations · Full text
A role for glucagon-like peptide-1 in the central regulation of feeding
Mandy D. Turton, Donal O’Shea, I. Gunn et al. · Nature · 1996 · 1.9K citations